Related Experiment Videos
Abnormal levels of platelet-specific proteins and mitogenic activity in myeloproliferative disease
1Unitat de Recerca Biomèdica, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Abstract:
It has been postulated that platelet-derived growth factor and platelet factor 4 (PF4) are involved in the imbalance of the mechanism of medullar stroma maintenance which triggers off the bone marrow myelofibrotic process. In this work we compare the PF4 and the beta-thromboglobulin (beta-TG) and mitogenic activity in platelet-poor plasma (PPP) and platelet extracts (PE) from patients with myeloproliferative disorders (MPD) with those of secondary thrombocytosis (ST) and normal volunteers. Statistically significant differences were found between MPD and ST patients or controls, but none between ST and controls in all the parameters studied. Maximal differences in platelet-derived factors (PDFs) between MPD and control groups were found in polycythemia vera patients. However, the relationship between the presence of myelofibrosis and abnormal levels of beta-TG, PF4 and mitogenic activity in PPP and PE was only observed in patients with agnogenic myeloid metaplasia (AMM). These results show that PDFs are specifically decreased in MPD platelets. Furthermore, no statistical correlation was found between PDFs and the number of platelets. However, other unknown factors or conditions would be necessary to develop myelofibrosis in MPD, which is present in AMM.
Insights
Platelet-derived factors (PDFs) are decreased in myeloproliferative disorders (MPD) platelets, unlike in secondary thrombocytosis. Myelofibrosis in agnogenic myeloid metaplasia (AMM) may involve other unknown factors.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Platelet-derived growth factor and platelet factor 4 (PF4) are implicated in myelofibrosis pathogenesis.
- Medullar stroma maintenance imbalance is a key factor in bone marrow myelofibrotic processes.
Purpose of the Study:
- To compare PF4, beta-thromboglobulin (beta-TG), and mitogenic activity in patients with myeloproliferative disorders (MPD) versus secondary thrombocytosis (ST) and healthy controls.
- To investigate the relationship between abnormal platelet-derived factors (PDFs) and myelofibrosis in MPD patients.
Main Methods:
- Quantification of PF4, beta-TG, and mitogenic activity in platelet-poor plasma (PPP) and platelet extracts (PE).
- Comparison of these factors across MPD patients, ST patients, and normal volunteers.
- Analysis of correlations between PDFs and the presence of myelofibrosis.
Main Results:
- Statistically significant differences in PDFs were observed between MPD patients and ST patients or controls.
- No significant differences were found between ST patients and controls for the studied parameters.
- Abnormal PDF levels correlated with myelofibrosis only in agnogenic myeloid metaplasia (AMM) patients, not other MPDs.
Conclusions:
- Platelet-derived factors are specifically decreased in MPD platelets.
- The development of myelofibrosis in MPD may require additional unknown factors beyond altered PDFs.